Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe.

To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab. This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study. Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients' treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p<0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p<0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p<0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p<0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p<0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey. In line with results from other studies, the SC form of daratumumab had less impact on patients' emotional burden than the IV form.

Informations de copyright

© 2024 Magarotto et al.

Déclaration de conflit d'intérêts

Julien Thevenon, Wafae Iraqi and Valeria Magarotto are employees/ shareholders of Janssen. Mrs Valeria Magarotto reports being an employee of Johnson and Johnson outside the submitted work. Xavier Guillaume, Dahbia Horchi, Bleuenn Rault, Marjorie Leclerc and Claire Graziani Taugeron are employees of Oracle France. Kate Morgan and Silene Ten Seldam are employees of Myeloma Patient Europe (MPE) which receives funding from the following sponsors: AbbVie, Amgen, Alexion, BeiGene, Binding Site, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline Therapeutics, Takeda, Sebia, Prothena, SkylineDx, Sandoz. Kate Morgan has been a member of the Janssen Global MM Collaboration Council since 2021. The authors report no other conflicts of interest in this work.